Ipsen completes acquisition of Memo Therapeutics

• Ipsen completed its acquisition of Memo Therapeutics, adding late-stage antibody potravitug to its rare-disease pipeline.
• Potravitug targets BK polyomavirus reactivation in kidney-transplant recipients, a condition managed mainly by reducing immunosuppression due to no approved targeted therapies.
• The asset’s profile is supported by Phase II SAFE KIDNEY II, described as the largest placebo-controlled trial in this patient population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220100PRIMZONEFULLFEED1001213809) on July 22, 2026, and is solely responsible for the information contained therein.